Key Trends Shaping China's Finished Dosage Formulation Market in 2025-2026

Published 1 November 2025 in Market Trends.

This article is kept with its original date and commentary. Market figures, forecasts and regulatory references reflect the time of writing and were not re-verified.

China's finished dosage formulation (FDF) market remains a cornerstone of the global pharmaceutical industry, projected to grow at a CAGR of 7-8% through 2030, driven by chronic diseases, aging population, and initiatives like Healthy China 2030.

Asia-Pacific CDMO market, led by China, is valued at ~$60 billion in 2025 with strong FDF focus.

Major Trends

Complex Formulations Rise: Increased production of sterile injectables, biosimilars, and controlled-release systems.
CDMO Expansion: Outsourcing growth at 8-9% CAGR, with investments in advanced facilities.
Regulatory Alignment: NMPA's ICH harmonization accelerates innovative FDF approvals.
Digital & Sustainable Practices: AI optimization and green manufacturing adoption.

These trends solidify China's leadership in affordable, high-quality FDF supply globally.

Bring the conversation to your own product.

Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.

Prepare a sourcing enquiry Discuss regulatory or CDMO support

Telephone+98 21 8888 3325 · office hours 09:00–17:00, Tehran

OfficeHaniya Parsan Darou, 3rd floor, No. 326, Zafar Street, Africa Boulevard, Tehran 1968734974, Iran

Emailcontact@hanpars.com